PharmaPoint Rheumatoid Arthritis - Drug Forecast and Market PharmaPoint Rheumatoid Arthritis - Drug Market | Page 6

6.2.5 Cimzia (certolizumab pegol) 132
6.2.6 Orencia (abatacept) 136
6.2.7 Actemra/RoActemra (tocilizumab) 142
6.2.8 Rituxan/MabThera (rituximab) 150
6.2.9 Inflectra/Remsima (infliximab biosimilar) 155
6.2.10 Xeljanz (tofacitinib) 158
6.2.11 Iguratimod/T-614 165
6.2.12 Methotrexate (Numerous Brands) 169
6.3 Biosimilars 172
6.3.1 Introduction 172
Browse Complete Summary Click Here @ http://www.radiantinsights.com/research/pharmapointrheumatoid-arthritis-global-drug-forecast-and-market-analysis-to-2023
6.3.2 Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases 174
6.3.3 Biosimilars in the Immunology Community 174
6.3.4 By the Numbers: Biosimilars in Development 175
6.3.5 The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry 179
6.3.6 Uptake of Biosimilars for RA is Expected to Vary by Market 180
6.3.7 Biosimilars' Forecast 183
6.4 Other Therapies 191

7 Unmet Need and Opportunity 193
7.1 Overview 193
7.2 Development of Cost-Effective Therapies 194
7.2.1 Unmet Need 194
7.2.2 Gap Analysis 195
7.2.3 Opportunity 195